BioSpace2d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
The Business Journals1mon
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
The company expects FDA approval this summer of its twice-a-year injectable HIV prevention drug lenacapavir. Gilead Sciences Inc.'s sales exceeded Wall Street expectations last year — thanks in ...
Morningstar2d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
“Gilead is fueling the next wave of innovation in HIV to help end the epidemic globally,” said Jared Baeten, MD, PhD, Senior Vice President, Virology Therapeutic Area Head. “Our ...